Why the study?
Does inhaled levosimendan improve pulmonary hemodynamics and RV function without decreasing systemic vascular resistance compared to intravenous levosimendan in patients with pulmonary hypertension undergoing mitral valve replacement?
Population
50 patients with pulmonary hypertension undergoing mitral valve replacement
Comparison
Inhaled levosimendan vs Intravenous levosimendan
Design
RCT, randomized into two groups
Follow-up
36 hours
Authors
Loading...
Inhaled levosimendan offers comparable pulmonary/RV benefits without SVR reduction in mitral valve replacement; extends route-specific levosimendan data in pulmonary hypertension.
Does inhaled levosimendan improve pulmonary hemodynamics and RV function without decreasing systemic vascular resistance compared to intravenous levosimendan in patients with pulmonary hypertension undergoing mitral valve replacement?
Inhaled levosimendan provides comparable pulmonary vasodilation and RV functional improvement to intravenous levosimendan but avoids systemic vasodilation in patients undergoing mitral valve replacement.
Kaur et al. (2018) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: